Stock HNSA N HANSA BIOPHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hansa Biopharma AB Mexican S.E.

Equities

HNSA N

SE0002148817

End-of-day quote Mexican S.E.
Other stock markets
 19:00:00 2023-03-15 EDT 		5-day change 1st Jan Change
160.8 MXN -.--% Intraday chart for Hansa Biopharma AB -.--% -.--%
05-31 Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial MT
05-31 Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
HANSA BIOPHARMA AB Stock Hansa Biopharma AB
-.--% 313M -
MODERNA, INC. Stock Moderna, Inc.
+23.13% 46.93B
B-
LONZA GROUP AG Stock Lonza Group AG
+36.98% 39.08B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.73% 38.48B
B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+28.09% 31.01B
B
CELLTRION, INC. Stock Celltrion, Inc.
-12.26% 26.14B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.57% 25.88B
B-
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.23% 12.53B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.56% 11.36B
B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.56% 10.65B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. HNSA Stock
  4. HNSA N Stock
  5. Ratings Hansa Biopharma AB